Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Buy at HC Wainwright
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a research note issued on Tuesday, Marketbeat.com reports. The firm currently has a $5.00 price target on the stock, up from their previous price target of $4.00. HC Wainwright’s price objective […]
Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) was upgraded by investment analysts at HC Wainwright from a “neutral” rating to a “buy” rating in a research note issued on Tuesday, Marketbeat.com reports. The firm currently has a $5.00 price target on the stock, up from their previous price target of $4.00. HC Wainwright’s price objective […]
